Calls
Source: S&P Capital IQ transcripts via Xpressfeed · latest indexed call 2026-04-23 · generated 2026-07-22.
Latest call digest
Molina Healthcare, Inc., Q1 2026 Earnings Call, Apr 23, 2026 · 2026-04-23T12:00:00
Q1 2026 call (April 23, 2026). Molina reported adjusted EPS of $2.35 on $10.2 billion of premium revenue and a 91.1% consolidated MCR, and reaffirmed full-year 2026 guidance of approximately $42 billion of premium revenue and at least $5 in adjusted EPS. Management characterized the quarter as solid but against modest expectations, following a 2025 that swung from an initial $24.50 EPS outlook to $11.03 delivered.
The gap between prepared remarks and the Q&A was one of tone rather than fact. Prepared remarks leaned optimistic: Medicaid trend was modestly favorable, the January rate updates came in as expected, the acuity-shift pressure of 2025 did not recur, and the newly converted Medicare duals products were off to a good start. Yet management repeatedly declined to raise guidance, invoking a "time tested" preference for two quarters of data after 2025's volatility. Notably, Q1 Medicaid trend annualized would run below the 5% full-year assumption, but management would not yet call it.
The one guidance change was mechanical: same-store Medicaid attrition was raised from a 2% to a 6% decline (California, Illinois, New York, Texas, with California's undocumented population singled out), offset by higher Marketplace revenue so that the $42 billion premium figure held. Management argued the higher attrition carries no incremental acuity because low- and no-utilizers are at their lowest recorded level. An Investor Day on May 8 was flagged for the 2029 outlook; the $42 billion / $5 baseline will not be updated there.
Participant coverage from the latest call.
| Group | Participants | Count |
|---|---|---|
| Management | Operator; Jeffrey Geyer — Head of Investor Relations, Molina Healthcare, Inc.; Joseph Zubretsky — President, CEO & Director, Molina Healthcare, Inc.; Mark Keim — Senior EVP, CFO & Treasurer, Molina Healthcare, Inc. | 4 |
| Analysts | Andrew Mok — Director, Barclays Bank PLC, Research Division; Stephen Baxter — Senior Equity Analyst, Wells Fargo Securities, LLC, Research Division; Ann Hynes — Managing Director of Americas Research & Senior Healthcare Services Equity Analyst, Mizuho Securities USA LLC, Research Division; Kevin Fischbeck — Managing Director in Equity Research, BofA Securities, Research Division; Justin Lake — MD & Senior Healthcare Services Analyst, Wolfe Research, LLC; Sarah James — Research Analyst, Cantor Fitzgerald & Co., Research Division; Albert Rice — Health Care Services Analyst, UBS Investment Bank, Research Division; Scott Fidel — Research Analyst, Goldman Sachs Group, Inc., Research Division; John Stansel — Analyst, JPMorgan Chase & Co, Research Division; Erin Wilson Wright — Equity Analyst, Morgan Stanley, Research Division; Ryan Langston — Director & Senior Analyst, TD Cowen, Research Division; Hua Ha — Senior Research Analyst, Robert W. Baird & Co. Incorporated, Research Division; Lance Wilkes — Senior Analyst, Bernstein Institutional Services LLC, Research Division; George Hill — MD & Equity Research Analyst, Deutsche Bank AG, Research Division; Jason Cassorla — VP & Equity Research Analyst, Guggenheim Securities, LLC, Research Division | 15 |
Curated latest-call exchanges; one row per analyst topic.
| Analyst | Firm | Topic | What changed in Q&A |
|---|---|---|---|
| Andrew Mok | Barclays | Medicaid attrition drivers | Pressed on which states drive the 2% to 6% attrition step-up and the MLR read-through; management named California, Illinois, New York and Texas and argued no acuity impact. |
| Stephen Baxter | Wells Fargo | Acuity-shift baseline | Challenged whether the low/no-utilizer floor is truly a zero-acuity baseline given tighter enrollment management; deferred a longer view to Investor Day. |
| Kevin Fischbeck | BofA Securities | Reaffirm vs. raise | Asked whether holding guidance is normal Q2 convention or reflects unquantifiable unknowns; management framed it as prudence after 2025's inflection. |
| Justin Lake | Wolfe Research | Quarterly trend and acuity split | Requested quarterly Medicaid trend and the trend-versus-acuity split; management declined quarterly granularity, citing pure-period noise. |
| Scott Fidel | Goldman Sachs | Medicare duals vs. MAPD | Asked to parse continuing duals from the exiting MAPD product; management gave a roughly $5.5 billion, 94% MLR duals run-rate as the 2027 jumping-off point. |
| Michael Ha | Robert W. Baird | Low/no-utilizer definition | Pushed for the MLR buckets defining low utilizers; management declined to disclose the definition, saying the direction is down regardless of definition. |
Theme tracker
Themes are curator-classified across supplied calls.
| Theme | Status | Quarters mentioned | Read-through |
|---|---|---|---|
| Medicaid rate-versus-trend imbalance | persisted | Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026 | The central driver of the earnings reset. Medicaid cost trend was cited at roughly 3% through 2023, doubled to about 6% by Q3 2024 and 7.5% for full-year 2025, outrunning rate updates. Management consistently argues the market is 300-400 basis points underfunded and expects rates to catch up over time. |
| Redetermination acuity shift and low/no-utilizers | persisted | Q2 2023, Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026 | First raised as negligible in 2023, it became a quantified driver (about 250 basis points of 2025 trend) as low utilizers left the rolls. By Q4 2025 and Q1 2026 management argues the effect is largely behind them, using low/no-utilizer levels and stayer/leaver convergence as evidence. |
| Embedded earnings framing | persisted | Q2 2023, Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026 | A recurring device for future earnings power. The figure rose from $5.50 per share in 2023 to $8.65 through 2025 and above $11 after the Florida CMS win, used to reassure investors through the margin trough. |
| Marketplace exposure reduction | emerged | Q3 2025, Q4 2025, Q1 2026 | After Marketplace drove roughly half of the 2025 shortfall, management shifted from a growth stance to a deliberate roughly 50% premium cut, repricing up about 30% and prioritizing renewals. This reframing of a formerly favored segment is a clear signal of risk appetite. |
| Medicare duals focus and MAPD exit | emerged | Q3 2025, Q4 2025, Q1 2026 | Management narrowed Medicare strategy to dual-eligibles, converting MMP members to integrated FIDE/HIDE products and announcing an exit from traditional MAPD for 2027 (a roughly $1 EPS drag in 2026 that does not recur). |
| Risk-corridor buffer thesis | dropped | Q2 2023, Q2 2024, Q3 2024, Q4 2024, Q1 2025 | For roughly two years management leaned on risk corridors as the first cushion against trend (about 200 basis points of protection). As corridors depleted through 2024 and gave no benefit by Q4 2024, the talking point faded and is essentially absent by Q4 2025 and Q1 2026 – the loss of that downside protection is itself signal. |
Guidance ledger
Quotes, calls, and speakers are source-verified; outcomes are curator-classified.
| Verbatim guidance | Call | Speaker | Curator outcome | Outcome note |
|---|---|---|---|---|
| “Our full year 2025 adjusted earnings per share guidance is now expected to be approximately $14 per share, which is $5 below our prior guidance of $19 per share.” | Molina Healthcare, Inc., Q3 2025 Earnings Call, Oct 23, 2025 · 2025-10-23T12:00:00 | Joseph Zubretsky | missed | Full-year 2025 adjusted EPS was reported at $11.03 on the Q4 2025 call, below this $14 guide and the original $24.50 outlook. |
| “This early view of the 2026 earnings per share baseline should provide for an outlook for 2026, which likely approximates this year's updated full year guidance.” | Molina Healthcare, Inc., Q3 2025 Earnings Call, Oct 23, 2025 · 2025-10-23T12:00:00 | Joseph Zubretsky | missed | This implied a roughly $14 2026 baseline; the Q4 2025 call subsequently guided 2026 to at least $5, far below the preliminary view. |
| “Our 2026 adjusted earnings per share guidance is at least $5.” | Molina Healthcare, Inc., Q4 2025 Earnings Call, Feb 06, 2026 · 2026-02-06T13:00:00 | Joseph Zubretsky | pending | Reaffirmed on the Q1 2026 call after a quarter management described as modestly favorable to expectations. |
| “In Medicaid, 2026 rates are expected to average approximately 4% and will not offset medical cost trend projected at 5%.” | Molina Healthcare, Inc., Q4 2025 Earnings Call, Feb 06, 2026 · 2026-02-06T13:00:00 | Joseph Zubretsky | pending | On the Q1 2026 call management reaffirmed the 4% rate / 5% trend assumption and noted Q1 trend ran modestly favorable, but declined to lower the trend pick. |
| “which we reaffirm at approximately $42 billion of premium revenue and at least $5 in adjusted earnings per share” | Molina Healthcare, Inc., Q1 2026 Earnings Call, Apr 23, 2026 · 2026-04-23T12:00:00 | Joseph Zubretsky | pending | Held despite modestly favorable first-quarter trend; management said it will update after second-quarter results. |
Q&A pressure map
Question counts and firms are curator tallies; analyst coverage shown above.
| Topic | Questions | Firms | Pressure / response |
|---|---|---|---|
| Medicaid attrition and renewed acuity-shift risk | 4 | Barclays, Wells Fargo, Robert W. Baird, Deutsche Bank | The most-pressed topic on the Q1 2026 call. Four analysts probed whether the raised 6% same-store attrition brings a fresh acuity shift; management pointed each time to record-low low/no-utilizer levels and stayer/leaver convergence. |
| Why reaffirm rather than raise guidance | 3 | BofA Securities, Morgan Stanley, UBS | Analysts questioned whether the caution reflected unquantified unknowns after a favorable quarter; management repeatedly cited a 'time tested' preference for two quarters of data and said nothing unusual occurred in Q1. |
| Medicaid cost-trend composition | 2 | Wolfe Research, Bernstein | Requests for quarterly trend and the trend-versus-acuity split. Management addressed the annual picture and pure-period basis but declined the quarterly granularity requested. |
| Low/no-utilizer definition | 2 | Wells Fargo, Robert W. Baird | Analysts sought the specific MLR buckets defining a low utilizer. Management confirmed the direction is down but explicitly declined to disclose the definition or the model, so the definitional detail requested went unanswered. |
Language shifts
Only language evidence verified against the referenced component is shown.
| Observation | Verbatim evidence | Call ID | Component |
|---|---|---|---|
| Tone eased from 2025's 'unprecedented' trend language to guarded, expectations-adjusted optimism. | “We would characterize the results as solid under the circumstances but that characterization is against the backdrop of current modest expectations.” | 1986884066 | 2 |
| New confidence that the redetermination acuity shift will not recur, though still framed as a holding expectation rather than a certainty. | “Our expectation that the acuity shift trend that we had experienced in 2025 was behind us and would not recur is holding up.” | 1986884066 | 2 |
| A new recurring caution phrase, 'time tested,' introduced to justify not extrapolating one favorable quarter. | “We use the term time tested because I think it is prudent to see 6 months of results before updating our guidance, particularly coming off a highly volatile medical cost inflection environment in 2025.” | 1986884066 | 16 |
| On the prior call, management characterized the 2025 trend as an aberration, an assertion that underpins the 2026 recovery thesis. | “We believe the medical cost trend in 2025 was an aberration, an anomaly by historical standards.” | 1975844137 | 2 |
| 'Trough' entered the lexicon as management called the bottom of the Medicaid margin cycle. | “We believe our 2026 forecast for Medicaid is the trough for managed Medicaid margins.” | 1975844137 | 2 |
The call history documents a sharp reset – from a $24.50 initial 2025 EPS outlook to $11.03 delivered and a 2026 floor of at least $5 – around a Medicaid rate/trend gap management insists is cyclical rather than structural. Q1 2026's modestly favorable trend and the deliberate refusal to raise guidance are the first tentative evidence for the trough thesis; the May 8 Investor Day and first-half data are the real tests of whether rates catch up.